Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Summary

This phase II trial is studying how well dasatinib works in treating patients with relapse small cell lung cancer. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2007-04

Primary completion

2009-02

Completion

2013-04

Drugs

Indications